China NMPA Drug Inspection - Beijing Yanjing Pharmaceutical Co., Ltd. - Atorvastatin calcium tablets

The Heilongjiang Provincial Food and Drug Administration issued an announcement on October 11, 2018, to rectify information concerning drug supervision and sampling. This correction followed an earlier report (2018, No. 8) which identified two batches (161223 and 161229) of Atorvastatin Calcium Tablets as unqualified. These batches were initially attributed to Beijing Jialin Pharmaceutical Co., Ltd. However, subsequent investigation, initiated by an application from the named company and confirmed by the drug regulatory department, established that Beijing Jialin Pharmaceutical Co., Ltd. was not the actual producer of these substandard drugs. The products had failed critical identification tests using Ultraviolet Spectroscopy, indicating a significant quality violation. Operating within the regulatory framework of China's drug administration, the provincial authority's immediate required action was to publicly correct this inaccurate attribution, ensuring transparency and factual accuracy in drug sourcing and oversight. This correction implicitly underscores the need for further regulatory efforts to identify the true manufacturer of these non-compliant pharmaceuticals and address the root cause of the quality issues.